Sample size formulae for the Bayesian continual reassessment method

BACKGROUND In the planning of a dose finding study, a primary design objective is to maintain high accuracy in terms of the probability of selecting the maximum tolerated dose. While numerous dose finding methods have been proposed in the literature, concrete guidance on sample size determination is lacking. PURPOSE With a motivation to provide quick and easy calculations during trial planning, we present closed form formulae for sample size determination associated with the use of the Bayesian continual reassessment method (CRM). METHODS We examine the sampling distribution of a nonparametric optimal design and exploit it as a proxy to empirically derive an accuracy index of the CRM using linear regression. RESULTS We apply the formulae to determine the sample size of a phase I trial of PTEN-long in pancreatic cancer patients and demonstrate that the formulae give results very similar to simulation. The formulae are implemented by an R function 'getn' in the package 'dfcrm'. LIMITATIONS The results are developed for the Bayesian CRM and should be validated by simulation when used for other dose finding methods. CONCLUSIONS The analytical formulae we propose give quick and accurate approximation of the required sample size for the CRM. The approach used to derive the formulae can be applied to obtain sample size formulae for other dose finding methods.

[1]  Jianfen Shu,et al.  Dose‐escalation designs in oncology: ADEPT and the CRM , 2008, Statistics in medicine.

[2]  Ying Kuen Cheung Commentary on ‘Small-sample behavior of novel phase I cancer trial designs’ , 2013, Clinical trials.

[3]  M. Elkind,et al.  Stochastic approximation with virtual observations for dose-finding on discrete levels. , 2010, Biometrika.

[4]  Ying Kuen Cheung,et al.  Calibration of prior variance in the Bayesian continual reassessment method , 2011, Statistics in medicine.

[5]  Ying Kuen Cheung,et al.  Sequential Implementation of Stepwise Procedures for Identifying the Maximum Tolerated Dose , 2007 .

[6]  Anastasia Ivanova,et al.  Escalation, group and A + B designs for dose‐finding trials , 2006, Statistics in medicine.

[7]  C. Ahn,et al.  An evaluation of phase I cancer clinical trial designs , 1998 .

[8]  J O'Quigley,et al.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.

[9]  Shing M. Lee,et al.  Model calibration in the continual reassessment method , 2009, Clinical trials.

[10]  Ying Kuen Cheung,et al.  Two‐Stage Designs for Dose‐Finding Trials with a Biologic Endpoint Using Stepwise Tests , 2008, Biometrics.

[11]  John O'Quigley,et al.  Non-parametric optimal design in dose finding studies. , 2002, Biostatistics.

[12]  Ying Kuen Cheung,et al.  Coherence principles in dose-finding studies , 2005 .

[13]  Y K Cheung,et al.  Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities , 2000, Biometrics.

[14]  John O'Quigley,et al.  Consistency of continual reassessment method under model misspecification , 1996 .

[15]  Jay Bartroff,et al.  Approximate Dynamic Programming and Its Applications to the Design of Phase I Cancer Trials , 2010, 1011.6509.

[16]  Ying Kuen Cheung,et al.  A Simple Technique to Evaluate Model Sensitivity in the Continual Reassessment Method , 2002, Biometrics.

[17]  J O'Quigley,et al.  Continual reassessment method: a likelihood approach. , 1996, Biometrics.

[18]  W J Shih,et al.  Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials. , 2001, Biostatistics.

[19]  M. Tighiouart,et al.  Number of Patients per Cohort and Sample Size Considerations Using Dose Escalation with Overdose Control , 2012 .

[20]  S. Durham,et al.  A random walk rule for phase I clinical trials. , 1997, Biometrics.